Lotronex Risk Factor Identification Is Prerequisite To Return, FDA Says
Executive Summary
GlaxoSmithKline and FDA are discussing ways to identify risk factors for Lotronex adverse events as a foundation for a risk management plan for the irritable bowel syndrome therapy.
You may also be interested in...
GSK Lotronex To Be Reviewed By FDA Drug Safety Cmte. In April
FDA's Drug Safety & Risk Management Subcommittee will review the safety of GlaxoSmithKline's withdrawn irritable bowel syndrome agent Lotronex (alosetron) on April 23
GSK Lotronex To Be Reviewed By FDA Drug Safety Cmte. In April
FDA's Drug Safety & Risk Management Subcommittee will review the safety of GlaxoSmithKline's withdrawn irritable bowel syndrome agent Lotronex (alosetron) on April 23
FDA Considering Lotronex Risk Management Advisory Cmte. Meeting For July
FDA is considering another advisory committee meeting for GlaxoSmithKline's Lotronex to discuss potential risk management options that would allow renewed use of the irritable bowel syndrome agent.